This website uses cookies

Read our Privacy policy and Terms of use for more information.




PSA's Sunday Sound-Off: November 15, 2026

PSA’s Sunday Sound‑Off: November 15, 2026

Fuel the Future of Psychedelic Journalism

Want to financially support original, independent reporting like this? You can! Donate at the link below, or just click the advertisement at the top of this article - no purchases or personal information sharing required

OPINION · The views expressed are the author's own and do not necessarily reflect those of Psychedelic State(s) of America.

When the Treatment Isn't Working, What Comes Next?

By Tim Jensen

U.S. Marine Corps Veteran | Chairman & President, Grunt Style Foundation

I served in Iraq from 2004 to 2005 as an infantry squad leader with 2nd Battalion, 24th Marines, in the Triangle of Death. Like many veterans, I came home carrying experiences that do not simply disappear when a deployment ends.

For too many veterans, the path to treatment becomes a cycle: an appointment, a prescription, another appointment, another prescription. Medication and conventional psychotherapy have helped countless veterans, and we should never diminish the work of the clinicians who provide that care. But we also have to be honest about the veterans who are not getting better.

I have heard veterans express their frustration in unmistakable terms: "The VA just hands out pills."

That statement does not describe every VA provider or every veteran's experience. But it reflects a real concern that deserves an answer. When a treatment is not working, what comes next?

A War Cry for Change

Through the Grunt Style Foundation's War Cry for Change, we are advocating for a more accountable and informed approach to veteran mental health care.

Veterans deserve informed consent. They deserve to understand the benefits, risks, and alternatives associated with their treatment. They deserve responsible medication management, including careful consideration of deprescribing when clinically appropriate. And they deserve a health care system that measures success by more than the number of appointments completed or prescriptions written.

We must also be willing to examine emerging treatments. That does not mean accepting every new therapy as a solution. It means asking serious questions, funding rigorous research, and creating a responsible pathway for promising treatments to be evaluated.

Psychedelic-assisted therapies, cannabinoid-based treatments, and other novel approaches are receiving increased scientific attention. The evidence is not uniform. Some interventions remain investigational, and their risks, effectiveness, and appropriate uses must be established through careful research. But veterans should not be left out of that work simply because the treatments are unfamiliar or the regulatory landscape is complicated.

The question is not whether every emerging treatment belongs in the VA. The question is whether the VA has the research infrastructure to determine which treatments may safely and meaningfully help veterans.

The VA already has an extraordinary foundation for medical research. It has a national health care system, experienced clinicians, academic affiliations, research programs, and a population of veterans whose health needs deserve sustained scientific attention.

But a collection of research projects is not the same as a coordinated national strategy.

Novel therapeutics require more than isolated studies or individual champions. They require institutional leadership, dedicated research capacity, clinical expertise, academic partnerships, long-term evaluation, and a process for translating credible findings into clinical practice.

The VA needs a structure that can bring those pieces together.

That structure should rest on two complementary pillars: a national network of Centers of Excellence and a National Office of Novel Therapeutics.

Centers of Excellence: Put the Science Where It Belongs.

Centers of Excellence should serve as the scientific and clinical foundation of this effort.

These should not simply be names attached to existing programs. They should be designated institutions with qualified leadership, dedicated resources, clinical expertise, research capabilities, and measurable responsibilities.

Their work should include:

  • Conducting clinical and translational research into novel and emerging therapies.

  • Supporting investigator-initiated research and multi-site clinical trials.

  • Building academic partnerships with leading universities and research institutions.

  • Evaluating safety, effectiveness, durability of outcomes, and potential adverse effects.

  • Developing evidence-based clinical protocols when the science supports them.

  • Training clinicians and researchers in emerging treatment approaches.

  • Sharing findings and lessons across the VA health care system.

The Centers should be capable of pursuing research questions that matter to veterans, including PTSD, depression, chronic pain, substance use disorders, sleep disturbances, and other conditions that affect quality of life.

They should also evaluate outcomes that matter beyond a clinical scale. Are veterans returning to work? Are they reconnecting with their families? Are they sleeping? Are they functioning in their daily lives? Are benefits lasting? What adverse effects are occurring?

And when a treatment does not work, that information must be documented and shared, too.

The objective is not to promote a particular therapy. It is to build the institutional capacity to determine what works, for whom, under what circumstances, and at what risk.

Communities of practice have an important role. They allow clinicians, researchers, and administrators to exchange experiences, discuss emerging evidence, share lessons, and identify challenges in delivering care. The VA should encourage and support those networks.

But collaboration alone is not infrastructure.

A community network does not necessarily have dedicated research capacity, institutional leadership, responsibility for conducting clinical trials, or the authority and resources to develop national clinical standards.

Centers of Excellence must provide something fundamentally different. They must be designated institutions with qualified leadership, dedicated resources, research capabilities, academic partnerships, clinical expertise, and measurable responsibilities for advancing the science.

Community networks can connect people and distribute knowledge. Centers of Excellence must be equipped and accountable to generate that knowledge.

Sharing knowledge is valuable. Building the institutions responsible for producing that knowledge is essential.

There is another lesson the history of medical cannabis research should teach us.

During the 1970s and in the decades that followed, the federal government and the VA were part of a broader history of investigating cannabis and its potential medical applications. Veterans were among the people whose experiences and medical needs helped bring attention to the subject.

Dr. Ethan Russo's professional history illustrates the connection between early medical interest in cannabis and its later commercial development. During his medical training, Russo encountered veterans using cannabis for medical purposes at the Palo Alto VA. He later became a Senior Medical Advisor and study physician for GW Pharmaceuticals, participating in the clinical development of cannabinoid medicines, including Sativex and Epidiolex.

That history raises an important question: when research begins with veterans, public resources, and federal medical institutions, who ultimately benefits from the knowledge generated?

Who controls the data? Who develops the resulting products? Who captures the commercial value? And do the veterans whose experiences helped advance the science share in the benefits?

We should not repeat a system in which veterans contribute to the advancement of medical knowledge while the resulting commercial opportunities are developed elsewhere, without meaningful public accountability or a clear commitment to veteran benefit.

This is not an argument against private-sector partnerships. Pharmaceutical companies, biotechnology firms, and academic institutions can bring valuable expertise, resources, and development capabilities to medical research.

But those partnerships must be structured transparently and in the public interest.

The VA should protect the independence and integrity of its research, establish clear policies governing data access and intellectual property, disclose financial conflicts, and ensure that research findings are made publicly available when legally and ethically appropriate.

Veterans who volunteer for research deserve to know how their participation will be used and what protections exist. The public deserves transparency when taxpayer-funded research contributes to commercial development.

And veterans should have a meaningful opportunity to benefit when the resulting discoveries become legitimate treatment options.

If veterans help make the science possible, they should not be forgotten when the benefits arrive.

A National Office to Lead and Coordinate the Effort.

Centers of Excellence cannot operate as disconnected institutions. They need national leadership, coordination, and accountability.

That is the role of a National Office of Novel Therapeutics within the VA.

The Office should establish national research priorities, coordinate the Centers, connect research with clinical operations, and ensure that promising findings do not remain isolated in individual institutions.

It should coordinate with relevant federal agencies, including the National Institutes of Health, the Department of Health and Human Services, the Food and Drug Administration, and the Department of Defense where appropriate. It should also support partnerships with universities and qualified research institutions.

Its responsibilities should include:

  • Establishing national priorities for novel therapeutics research.

  • Coordinating and overseeing the Centers of Excellence.

  • Developing consistent research, safety, and clinical evaluation standards.

  • Tracking research progress, outcomes, and gaps in evidence.

  • Supporting responsible translation of validated findings into VA clinical practice.

  • Ensuring accountability, transparency, and public reporting.

  • Coordinating with federal agencies and qualified academic partners.

The Office should also establish national standards for research independence, data governance, intellectual property agreements, publication transparency, and the disclosure and management of financial conflicts of interest.

When research involves VA resources or veteran participation, agreements with outside institutions and commercial partners should protect the integrity of the science, preserve appropriate public access to findings, and ensure that veterans' interests remain central.

The VA should not allow knowledge generated through veterans' participation and public investment to become inaccessible to the very population the research is intended to serve.

Importantly, the National Office should not replace the scientific leadership of the Centers or dictate the conclusions of individual studies. The Centers must retain the expertise and independence necessary to conduct credible research. The Office provides national strategy, coordination, oversight, and accountability.

The distinction matters: the Centers generate the evidence; the Office ensures that the evidence advances a coherent national effort.

Research that never reaches the veteran is not enough.

The VA needs a responsible process for evaluating credible findings and determining whether they should inform clinical practice. That process must account for scientific evidence, regulatory requirements, patient safety, clinician training, informed consent, and appropriate follow-up.

The VA already has experience evaluating treatments that once required new clinical pathways. Ketamine and esketamine, for example, demonstrate that the health care system can evaluate and incorporate treatments that differ from traditional approaches. Their clinical uses and regulatory status are distinct from those of classical psychedelics, and they should not be treated as interchangeable. But their development illustrates why the VA needs the ability to evaluate new options rather than simply wait for the future to arrive.

Any novel therapeutic research must be conducted with appropriate screening, informed consent, qualified professionals, safety monitoring, and compliance with FDA requirements and controlled-substance laws.

And the measures of success must be meaningful. We should evaluate symptoms, functioning, quality of life, durability, adverse events, and the outcomes veterans themselves identify as important. We should be careful not to claim that improvements in one measure automatically establish improvements in another, including suicide prevention. Those questions require direct, rigorous study.

A national infrastructure would allow the VA to build evidence systematically, learn from both positive and negative results, and make decisions based on science rather than hype, politics, or institutional inertia.

Veterans have already given enough. They should not have to navigate a health care system that cannot answer what comes next when the first treatment fails.

We do not need to abandon conventional medicine. We need to make sure conventional medicine is not the only answer the system knows how to offer.

The VA has the scale, the clinical expertise, the research history, and the responsibility to lead. What it needs now is the institutional structure to do so: Centers of Excellence capable of producing rigorous evidence, and a National Office of Novel Therapeutics capable of coordinating that work and translating credible findings into better care.

This is not about promising a miracle treatment. It is about giving veterans a health care system willing and equipped to find better answers.

When the treatment isn't working, the answer cannot simply be more of the same.

Our veterans deserve a system that keeps searching.

If you or someone you know is struggling, call or text 988 in the U.S. to reach the Suicide & Crisis Lifeline.

Editor’s Note: Tim Jensen is Chairman & President of the Grunt Style Foundation, which advocates for veteran mental health care reform through its War Cry for Change campaign. The views expressed are the author's own.

PSA ANNOUNCEMENT

Coming Soon: PSA’s PodWire, the Psychedelic Podcast Ecosystem all on One Wire

Psychedelic State(s) of America's PodWire logo: a U.S. map broadcasting on-air waves above the word PODWIRE and a rainbow audio wave

Psychedelic State(s) of America’s PodWire

Some of the sharpest conversations about psychedelic policy, science and culture happen on podcasts, but they’re scattered across dozens of feeds and apps.
The Psychedelic State(s) of America PodWire brings them together.

PodWire is Psychedelic State(s) of America’s new podcast desk: new episodes from PSA’s media partners and the psychedelic podcasts shaping drug policy, psychedelic science and psychedelic culture, all in one place. Here’s what’s coming down the wire:

🎙️ Spotlight: Our media partners’ shows, in depth, with episode features, clips and host spotlights shared across PSA’s newsletter, website and social channels.

📡 Live: Every new episode worth hearing, on one feed, playing straight from each show’s own feed so the downloads stay with the shows.

🎧 Studio: New voices, developed and produced by PSA, as the audio arm of PSA’s next-gen media incubator, built to help new shows find their footing.

Host or produce a psychedelic podcast?

Get your show listed and featured on PodWire. Tell us about it on the PodWire page: the submission form asks for your show’s public RSS feed, a short description and the beats it covers, plus a few sponsor and affiliation disclosures. We review every submission and reply by email, and shows join the live feed once they’ve published within the last 90 days.

Inclusion is not endorsement. Questions? [email protected]

PSA NewsWire Highlights of the Week: November 15, 2026

This Week's Highlights

📜 Law & Policy

Marijuana Moment logo

From our friends at Marijuana Moment

By Tom Angell

Editorial Disclosure: Marijuana Moment is a PSA media partner.

💰 Business

Reuters logo

Via Reuters

By Patrick Wingrove and Yasmeen Abutaleb

An HHS spokesperson told Reuters the voucher pilot is ongoing.

🎨 Culture

DoubleBlind logo

From our friends at DoubleBlind

By Damon Orion

Editorial Disclosure: DoubleBlind is a PSA media partner.

Enjoyed this column? Subscribe to Psychedelic State(s) of America and share this post with someone who should read it.

Until next time,

The Psychedelic State(s) of America Team

Psychedelic State(s) of America is committed to fostering rigorously diverse debate and discourse on all psychedelics-related topics. While PSA publishes a broad range of commentary and opinion pieces as part of our broader content offerings, that does not mean that PSA team members agree with every perspective published on our site. We welcome feedback and input on our editorial process, as well as submissions for consideration to be featured in PSA's Sunday Sound‑Off series. For feedback, submissions, and more information, contact PSA Founder Jack Gorsline at [email protected] 24/7/365.

Keep Reading